Multifaceted Implantable Anticancer Device for Potential Postsurgical Breast Cancer Treatment: A Single Platform for Synergistic Inhibition of Local Regional Breast Cancer Recurrence, Surveillance, and Healthy Breast Reconstruction

Abstract

In the initial publication, a project number was mistakenly omitted from the acknowledgements section. The updated acknowledgements are:

Fabrication of PEGylated SPIONs-Loaded Niosome for Codelivery of Paclitaxel and Trastuzumab for Breast Cancer Treatment: In Vivo Study

“…Scientists reported that the implantable multimodal therapeutic drug delivery systems will provide a potent platform for the postoperative treatment of breast cancer by providing synergistic cell growth inhibition in the tumor site due to the controlled release of DOX during a specific time under periodic hyperthermia. 45,46 This is an important finding in understanding the main strategy of drug release in our study. To the best of our knowledge, when the mats are immersed in the biological systems, according to the results from swelling, it can be claimed that groups with a higher content of TbNs start to adsorb water and start to swell before any drug release.…”

“…Our findings on the PTX release at least hint that employing AMF increases the rate of drug release, which means by employing AMF at the beginning of mat implantation it is possible to cause more drug release, and then by removing the AMF, the rate of drug release is reduced to fight if there is tumor survival. Scientists reported that the implantable multimodal therapeutic drug delivery systems will provide a potent platform for the postoperative treatment of breast cancer by providing synergistic cell growth inhibition in the tumor site due to the controlled release of DOX during a specific time under periodic hyperthermia. , …”

<p>Modified methods of nanoparticles synthesis in pH-sensitive nano-carriers production for doxorubicin delivery on MCF-7 breast cancer cell line</p>

“……”

Implantable Devices for the Treatment of Breast Cancer

“…An implantable anticancer device (IAD) with the functionality to prevent LRR of breast cancer as well as enhancement of breast reconstruction during/after therapy was proposed [65]. Superparamagnetic graphene oxide (SPGO) was fabricated by incorporating superparamagnetic iron oxide nanoparticles (SPION) with nanographene oxide [65,66].…”

“…An implantable anticancer device (IAD) with the functionality to prevent LRR of breast cancer as well as enhancement of breast reconstruction during/after therapy was proposed [65]. Superparamagnetic graphene oxide (SPGO) was fabricated by incorporating superparamagnetic iron oxide nanoparticles (SPION) with nanographene oxide [65,66]. DOX was conjugated with the resultant SPGO nanocomposite, then incorporated into a flexible and biocompatible polyurethane (PU) nanofiber matrix (SPGO DOX NF) (Figure 5).…”